2MSR image
Deposition Date 2014-08-05
Release Date 2014-08-20
Last Version Date 2024-05-15
Entry Detail
PDB ID:
2MSR
Keywords:
Title:
Solution structure of LEDGF/p75 IBD in complex with MLL1 peptide (140-160)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
100
Conformers Submitted:
20
Selection Criteria:
structures with the least restraint violations
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Histone-lysine N-methyltransferase 2A
Gene (Uniprot):KMT2A
Chain IDs:A
Chain Length:21
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:PC4 and SFRS1-interacting protein
Gene (Uniprot):PSIP1
Chain IDs:B
Chain Length:88
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Validation and Structural Characterization of the LEDGF/p75-MLL Interface as a New Target for the Treatment of MLL-Dependent Leukemia.
Cancer Res. 74 5139 5151 (2014)
PMID: 25082813 DOI: 10.1158/0008-5472.CAN-13-3602

Abstact

Mixed lineage leukemia (MLL) fusion-driven acute leukemias represent a genetically distinct subset of leukemias with poor prognosis. MLL forms a ternary complex with the lens epithelium-derived growth factor (LEDGF/p75) and MENIN. LEDGF/p75, a chromatin reader recognizing H3K36me3 marks, contributes to the association of the MLL multiprotein complex to chromatin. Formation of this complex is critical for the development of MLL leukemia. Available X-ray data represent only a partial structure of the LEDGF/p75-MLL-MENIN complex. Using nuclear magnetic resonance spectroscopy, we identified an additional LEDGF/p75-MLL interface, which overlaps with the binding site of known LEDGF/p75 interactors-HIV-1 integrase, PogZ, and JPO2. Binding of these proteins or MLL to LEDGF/p75 is mutually exclusive. The resolved structure, as well as mutational analysis, shows that the interaction is primarily sustained via two aromatic residues of MLL (F148 and F151). Colony-forming assays in MLL-AF9(+) leukemic cells expressing MLL interaction-defective LEDGF/p75 mutants revealed that this interaction is essential for transformation. Finally, we show that the clonogenic growth of primary murine MLL-AF9-expressing leukemic blasts is selectively impaired upon overexpression of a LEDGF/p75-binding cyclic peptide CP65, originally developed to inhibit the LEDGF/p75-HIV-1 integrase interaction. The newly defined protein-protein interface therefore represents a new target for the development of therapeutics against LEDGF/p75-dependent MLL fusion-driven leukemic disorders. Cancer Res; 74(18); 5139-51. ©2014 AACR.

Legend

Protein

Chemical

Disease

Primary Citation of related structures